The Peptide Pulse — Episode 20: Growth Hormone Peptides Explained: Recovery, Body Composition, Sleep & What You Need to Know

In this episode of The Peptide Pulse, Dr. Adam dives deep into one of the most talked about and most misunderstood topics in the peptide space: growth hormone peptides.

Dr. Adam breaks down the major categories of growth hormone peptides, what they actually do, and how they interact with the body's natural systems. From recovery and body composition to lean mass, sleep, and overall vitality, this episode covers the full picture of what these compounds can and cannot do.

If you have been curious about growth hormone peptides but find yourself lost in the jargon and conflicting information, this episode cuts through the noise and gives you the clarity you need to navigate the space with confidence. No hype, no shortcuts, just the science and what it actually means for your health.

📍 Connect & Subscribe:

YouTube: @thepeptidepulse
 Instagram: @dradamboender
 Website: https://peptideresearcher.com/

🎧 Listen on: Spotify | Apple Podcasts | Buzzsprout

💬 Question for You:
Whats one Peptide or Peptide Stack your wanting to start trying in the new year? 
Drop it below 👇

Transcript

SPEAKER_00 0:14

Hey everybody, welcome back to the peptide pulse. And today I want to talk about growth hormone peptides as a whole because this is one of the most talked about and also most misunderstood conversations in the peptide space. You know, I have patients, clients, people all over the world that are asking about these compounds all the time. They want to know, you know, what helps with recovery, what helps with body composition, what helps with lean mass, what helps with sleep, what helps with feeling younger. And so most people are hearing peptide names and honestly not understanding the framework that's actually behind them. And that's really where the conversation and even the confusion starts. Because, you know, if you don't understand the difference between the major categories when it comes to growth hormone peptides, then every peptide just kind of sounds like the next promise. So today, I really want to simplify this. I want to take it back so that you have a better understanding. I really want to walk you through what growth hormone peptides are, how to think about growth hormone releasing hormones peptides versus growth hormone releasing peptide peptides. That's right. They're two different things. Each peptide is a little bit different, and I know it can get confusing. So I really am going to slow this down so you have a better understanding. You know, where the major players fit, why certain peptides get more attention than others, and how clinicians should really think through patient complaints or how you're thinking through the things that you're dealing with without overcomplicating the overall conversation, because there was a lot of noise out there. So again, this is about creating simplicity, helping you to have a better understanding. You know, one of the best lines from literature says that the decline of growth hormone secretion observed in aging is actually associated with your body composition. And so, really, what that means is like as you age, less growth hormone is being produced or secreted from your pituitary gland. And because of that, your body's not going to hold on to that composition, that muscle tone, which actually muscle tone isn't real, but it's going to create muscle density loss over time. And that research actually helps to explain why this conversation is so relevant in the first place. Because honestly, if you really want to look at that research, it's actually showing that by the time you hit 30 years old, men and women, your natural growth hormone production drops by about 10 to 15% every single decade. And I know that we look at a lot of uh people and we talk about like hormone replacement therapy, but what's missed a lot is actually the growth hormone therapy and not necessarily like things like testosterone, which everybody goes to. And I really want to be able to help break this down. There are two different categories, but let's not miss this one. So, you know, really patients don't usually walk in and say, hey, I think my growth hormone pulsativity is actually declining. Wait, this thing's not working, right? So, you know, what they do say is I don't recover like I used to. I cannot lose that abdominal fat that used to come off like super easy. You know, I feel weaker, I sleep worse, I just do not feel as resilient as I used to. You know, that's the real entry point into this whole category and this understanding. In fact, growth hormone secretagogues really are a staple in what I call kind of almost a tier one of moving into uh peptide-related therapies and modalities, specifically when I'm working with clinicians and physicians, because it really is a base. You know, the first thing to understand is that growth hormone peptides are not all doing the same thing. Some work more upstream, others work more like amplifiers. The cleanest distinction is this. So growth hormone releasing hormone peptides is like the signaling side. And growth hormone releasing peptide peptides is the secretagog or the ghrelin receptor side. Growth hormone releasing hormones is like, you know, sending the order, while the growth hormone releasing peptide is like ringing the bell. It's like, hey, hey, let's do this thing. That one distinction really clears up a huge amount of confusion within the space. You know, when we start looking at growth hormone releasing hormones, you know, you're dealing with uh compounds that really tell the pituitary to release more of the body's own natural growth hormone. And I really want that to be understood. This is not pushing the body into something. If you take uh, say, an exogenous growth hormone, a lot of bodybuilders review this, and not even bodybuilders, the Jim Bros, all these guys, you know, they're taking an exogenous, which actually is an injection that like floods the bloodstream with growth hormone. That's not what this is doing. This is again, it's sending a signal to the pituitary gland so that your body can naturally release what it needs to release to have that effect. You know, on the growth hormone releasing peptide side or the ghrelin mimetics, meaning it's it's mimicking ghrelin receptors, you're actually dealing with compounds that stimulate growth hormone release through the growth hormone secretogog receptor. Okay, so differences between the two. And this is not just about, you know, naming a specific peptide. It it literally changes the whole clinical feel of what compound you're using. And we are going to get into what these compounds are here in a little bit. But just understand, again, we've got some that are sending the signal, some are ringing the bell. We just need to bring that clarity. You know, there's a real reason why one of the classic papers on this subject states that ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretigog receptors. And I know you're gonna ask which peptide is which, we'll get there, don't worry. You know, that line line actually comes from Sun and colleagues in PNAS, so it's it's PANS, um, and it helps us. Uh, I'm sorry, it's PNAS, just kidding. PNAS, I said it wrong. That's right, I'm human. But this research actually helps remind us that some of the compounds are tied not to growth hormone release, but to actual hunger signaling. And there's a big distinction in that. So, right away, this tells you something very important. Not all growth hormone peptides are equally clean. And I'm not talking about dirty, clean, black market, gray market. It's how they respond to a system, a direct signal or sometimes even an indirect signal. Not all of them are equally selective, and not all of them should be discussed with patients in the same way. So, this category gets attention because it lives right in the middle of some of the most common complaints in longevity, performance, and wellness. So think about this from recovery, body composition, visceral fat. And again, just so that you have an understanding, visceral fat, that's not that fat that you see on the outside. It's that fat that's internal, surrounds the organ tissue. That visceral fat increase can increase the risk for heart disease, liver disease, uh, pancreatitis, a lot of these other issues. So, so that's a big one. Sleep quality, lean mass, resilience, that recovery, and growth hormone physiology, it really matters within all of these categories and how you choose which you're going to use. It's not that simple. You know, I go to the gym often, I love to work out, but I can tell you when I'm at the gym and I have guys come up to me or in just general conversations, like, oh dude, you got to take CJC 1295, oh, you got to take SOMORLINE, or you got to take Tesla Moralin, or you gotta take I it's like, why? Why this one, why that one? Just because you had a specific result doesn't mean that it's gonna work for every single person. There's different needs, which I obviously will continue to say as always, there needs to be guidance. Don't just buy the stuff and start because there can be dangers associated with these as well. Make sure you have guidance. You know, as as growth hormone signaling declines with age, changes in body composition, function, they become more noticeable. You know, that does not mean that every aging symptom is actually a growth hormone problem. It's just one of the common things that happens. But it does mean that growth hormone peptides become a very attractive category for clinicians, for patients looking at recovery, adipose. It does mean growth hormone peptides become a very attractive category for clinicians and patients, looking at recovery, adiposity, and age-related change. Now, when I talk about adiposity, that's like fat tissue. It's uh the concentration of that fat tissue both on the inside and outside, surrounding those organs, and the external. So the problem is that the marketing conversation has moved faster than the framework conversation. Meaning, like, so what happens here? People hear peptide names, they hear outcomes, they hear stacks, but they never get taught how to actually think through the process of which is going to be best for them. And quite honestly, I think that matters more than anything. Because not everybody is exactly the same. Not simple, not every symptom, not every category that you're coming to saying, hey, I want this, you know, is going to give the same result. So on the growth hormone releasing hormone side, so again, growth hormone releasing hormone peptides, the main names that tend to come, yep, that's right, here we go. You've been waiting for this, that tend to come up are SMORlin, Tesomorlin, and CJC1295. On the growth hormone peptide peptides or secretagog side, the main names people talk about are ipomorlin, hexorelin, and mk677. Now, these names are often grouped together as if they are basically interchangeable. And I want you to know something. And listen, they are not. Tesamorlin is probably the most evidence-anchored conversation in this category. And so, really, in human trials, what tesmorlin has shown is that it reduces visceral fat in that setting. And it actually is studied for, and and the paper summarized in it talking about this. This is really cool, guys. Now, listen, Tesamorlin, the study on this, it reduces visceral fat by up to approximately 18%. That's right. That's quite a bit. You know, we all hear about like the GLPs and all these other products, but tesamorlin in of itself helps reduce that visceral abdominal fat internally, which can help. And again, don't quote me, I'm just giving you information. But if we know that we reduce visceral fat here, um, again, just listen, that decreases risk for things like heart disease. It decreases risk for issues with the abdominal, it helps with the liver, it helps with multiple organ processes because you're reducing that fat tissue internally. It's important. CJC 1295 gets a lot of attention because it has been published in uh honestly in the human endocrine data showing sustained increase in growth hormone and IgF1. And so this research, again, describing this sustained dose-dependent increase in growth hormone IGF 1 levels is huge because it, I mean, it literally is going back to data because what do we hear all the time? Oh, there's not enough research on these peptides. There is research. But again, you have to look at then what do you do? How do you test? You want to make sure that these things are right. You know, Ipamorelin, again, it's another popular growth hormone because people often talk about it as a cleaner secretagogue in that conversation. Hexorelin, much stronger, but it's also very clean, not quite as clean as ipomorelin. Most people don't hear of hexorelin unless they're willing a big jump in that growth hormone. Not recommend it. I don't usually, I've actually never used it. That it's not a big one for me. MK677, it's a very popular one. It's uh convenient because it's actually oral. And so people can take that as a capsule. And in in older adults, it is enhanced pulsative growth factor, hormone secretion, and increased fat-free mass. That's called muscle tissue. Uh, but that does not mean it solves the whole clinical picture, it's just a part of it. Again, we've got to look at really what that person is needing when they're starting to take one. So, this is the part people need to really hear. So, I want you to listen in on this. These peptides live in the same family conversation, but they are not all doing the same job. Did you hear that? These peptides live in the same family conversation, but they are not doing the same job. One of the biggest mistakes people make in confusing mechanism with evidence. Did you hear me? One of the biggest mistakes people make is confusing mechanism with evidence. Mechanism is what the compound is supposed to do. Evidence is what it actually is shown to do. And that's a very important distinction. Tesimorlin has the clearest outcome data in humans on defined clinical settings. So it's it's it's shown that it actually does that with that visceral fat breakdown. CJC1295 has obviously useful human endocrine data showing growth hormone and IgF-1 changes in healthy adults, whereas like MK677 showed increases in pulsative growth hormone secretion and fat-free mass in healthy older adults. So, again, there is data and research that shows these things. A lot of the other growth hormone peptide conversations, especially in the wellness and performance spaces, is a mix of physiology, practitioner experience. And honestly, it's it's not what we're looking at, but rather than the same quality of outcome data. So it's almost like they're taking these other products and they're trying to push them into the same categories. And they're not. You have to look at the differences. So that does not mean that it's useless or not that these other products don't work. It just means clinicians should actually stop pretending, or people should stop pretending when they're utilizing these, that all of the evidence is equal. Some peptides have a chart, some mostly have just a story. You know, semorlin is actually another one that's great. It's actually been utilized for adolescence and hypogonadism. So it's helping with height and there's specific dosing protocols. Now, I'm not sitting here telling you to if your child isn't growing fast enough to go find SMORLin and start injecting it. There must be clinical uh guidance, and there's a proper way to do things and an improper way to do things. So, again, a lot of these stories that we hear does not mean it's going to work across the board. Now, inside the broader growth hormone peptide conversation, CJC 1295 deserves some special attention. Why? Because it exposes a lot of the confusion within the category. So, so what does that mean? We we look at CJC and it sits on that growth hormone-releasing hormone side of this conversation. It is a modified analog. Okay, so meaning it's been shifted and changed slightly, designed to prolong the signaling effect. So your body produces growth hormone. This specific one, CJC 1295, has been slightly modified so that signal can actually last longer. And this is where people will see CJC DAC or CJC NODAC. And again, what does that mean? What's DAC versus no DAC and why does it matter? So these are not interchangeable conversations, meaning there is one or there's the other. NODAC is the shorter acting pulse style discussion, meaning it's gonna go really fast, it's gonna get into your system, the half-life is is very, very short. DAC, which means drug affinity complex, is the longer exposure uh exposure discussion. So again, it's gonna last longer within the system. And in fact, the the NODAC is gonna last, it can last a few hours, whereas DAC can actually last up to like six, even seven days within your system. So if you have something that has the drug infinity complex, you definitely do not want to be dosing that every single day, or even five days on, two days off, or switching up that dosing. The simplest way to explain this is no DAC is like a knock on the door, and DAC keeps that messenger in the building much longer. So they knock on the door, they come in, and they have a great conversation. Sometimes they last and stay longer than they want. And then the next messenger comes if you're doing too much too quick. That longer exposure is exactly why CJC gets so much attention. It is also why clinicians really need to be more precise, and that's right, precise is key when they start talking about it or even recommending it. Because when somebody casually says CJC and you should just use it, that does not tell you enough. It says, you know, which version is it? What's the exposure profile? What is the actual goal? What is the patient or the person experiencing when they're on it? Human studies showed sustained growth hormone and IGF-1 elevation with CJC 1295, and growth hormone pulsativity was still preserved. So that is part of why it became such an important peptide in this conversation, why kind of everybody jumps to it? It's showing that it it boosted and it works. But CJC is also the place where people start to get misunderstood reactions. Some of these reactions are just local site injections, and that can be formulation issues. So that that redness within the belly or the injection site, some are vascular or even systemic effects like warmth, flushing, some are even downstream effects on growth hormone and IgF elevations like edema, puffiness, or even glucose drift. So shifting that glucose, there can be some serious effects. That's why, again, you must have guidance when utilizing this. Don't just randomly start taking this. You also have to look at your source. If you have a bad source, what can happen is drug affinity complex or no, DAC, no DAC. What can happen is these peptides, these amino acid chains, if they're reconstituted wrong or there's other additives or impurities within there, these amino acids can flip on each other. They can become proteins, they can coagulate, and they can have adverse reactions. And then your body is going to have a bad reaction. So with that, it's a smarter framework than just saying, hey, I reacted badly to something. There is one of the biggest mistakes in this category that people say, I just had a bad reaction. When a patient or somebody stops responding, people automatically assume the answer is more. Like I just need to take more of it, or it's not working for me anymore. Sometimes the body isn't going to accept it. Don't think more dose, don't think more frequency, don't think more stacking. You know, honestly, it becomes a little bit more complex and there has to be a better understanding. It's not the answer to give more, stack more, and do more. Sometimes the issue is the wrong peptide for the wrong complaint or the wrong situation. Sometimes the issue is appetite and glucose baggage on the ghrelin side. And sometimes the issue is fluid retention. Sometimes the issue is product quality or the formulation complexity. Maybe it's flipped over, maybe it reconstituted wrong. I mean, so there could be some issues there. Sometimes the issue is that the patient's goal was never actually clear in the first place. This is why the patient complaint or the patient's process of what they're bringing to you matters more than the actual hype around the vial or the product. You want to start with that complaint. Whatever you're sitting here, it's like, hey, I've been told to take this. Well, why? Why were you told to take it? Did you even ask? Was it even on your radar? And all of a sudden you saw uh somebody walking in that you're like, oh, they're lean, they're ripped, they're jacked, they're this is where I want to be. That doesn't mean you should do what they're doing. You know, again, if the patient says, you know, I do not want to recover or I don't recover well, think things like sleep, repair, pulse quality, training tolerance. Are you working out too much? Are you not recovering fast enough? And what is the resilience there? If a patient says, you know, my belly fat will not move, it's just stuck, think body composition, visceral fat biology, insulin context, and and where the best evidence actually sits for those specific things. If the patient says, I mean, I just feel weaker, like I've been in that place, I just don't feel strong anymore. Like I just'm not getting there. Think of like the lean mass preservation. So when your body breaks down fat tissue and also muscle tissue, there's a there's a reason why this happens. As we age, that growth hormone isn't preserving that muscle tissue the same way. It's just not. It just doesn't do it. And so what we need to do is we need to preserve that. And that's where growth hormone actually comes in. It actually increases the recovery reserve. And whether that whole foundation is off or not could say, hey, maybe we're going to utilize this growth hormone or this growth hormone secreting peptide. And so if the patient says things like, hey, I'm hungry all the time, I'm puffy, my glucose is creeping up, if they're checking that or seeing it, um, you know, that could and should immediately make you more cautious about the certain secret conversation that they're on. Probably something like a CJC, IPA combo. There could be issues there. You know, if the patient says, you know, I want anti-aging, you know, honestly, that's not necessarily a peptide plan. That's an individual or an invitation to the clarity of the real endpoint. You know, that that patient gives you a headline, like, hey, I just want anti-aging, I want longevity. You know, your job is to find the physiology underneath it. So the goal is not just how to give a peptide or this peptide's name or whatever. It's the goal to understand that framework. And it may not even be a growth hormone secreting, you know, hormone peptide or growth hormone secreting peptide peptide. Understand where the main compound fits. And I think that's very vitally important. Understand where the stronger evidence sits. Understand why CJC matters, but also why it should not take over the whole conversation. And most importantly, understand how the translation of the patient's complaint into a cleaner clinical decision is going to be made. Because once you do that, the whole category gets less noisy. There's less hype, there's less guessing, there's less confusion, and a lot more clarity on what you should actually be doing. That is really the point. It's not just more peptide talk or more stacking, it's better peptide thinking. So I just want to say thank you so much for listening. Um, this is a I'm I'm passionate about this topic. I love talking about growth hormone secretion. And the different peptides and the way that you can actually bundle them together, but really listen to that conversation that the person is talking about or the one that you're having when you're trying to make that next step so that you can actually make the right choice for yourself and actually bring that to your clinician. Make sure that you've got guidance. Thank you again. I look forward to seeing you on the next one.